share_log

Novavax | 8-K: Poll Results of 2024 Stockholders Meeting

Novavax | 8-K: Poll Results of 2024 Stockholders Meeting

諾瓦瓦克斯醫藥 | 8-K：2024年股東大會會議決議公告
美股sec公告 ·  06/14 16:07
Moomoo AI 已提取核心訊息
On June 13, 2024, Novavax, Inc. held its Annual Meeting where several key proposals were voted upon by stockholders. The stockholders approved the amendment and restatement of the Amended and Restated 2015 Stock Incentive Plan, which will increase the available shares for issuance by 6,500,000. Additionally, the 2013 Employee Stock Purchase Plan was amended and restated to increase the available shares by 1,000,000. The stockholders also elected three Class II directors to serve a three-year term, approved the executive compensation for 2023, and ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024. The proposals were detailed in the 2024 Proxy Statement filed with the SEC on April 29, 2024, and amended on June 5, 2024. The full text of the amended plans is incorporated into the Current Report on Form 8-K as exhibits.
On June 13, 2024, Novavax, Inc. held its Annual Meeting where several key proposals were voted upon by stockholders. The stockholders approved the amendment and restatement of the Amended and Restated 2015 Stock Incentive Plan, which will increase the available shares for issuance by 6,500,000. Additionally, the 2013 Employee Stock Purchase Plan was amended and restated to increase the available shares by 1,000,000. The stockholders also elected three Class II directors to serve a three-year term, approved the executive compensation for 2023, and ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024. The proposals were detailed in the 2024 Proxy Statement filed with the SEC on April 29, 2024, and amended on June 5, 2024. The full text of the amended plans is incorporated into the Current Report on Form 8-K as exhibits.
2024年6月13日，Novavax公司舉行年度股東大會，股東們對幾項關鍵提案進行了投票表決。股東批准修訂並重申2015年經修訂的股票激勵計劃，將增加可發行股票數量650萬股。此外，2013年職工購股計劃也經修訂並重申，可發行股票數量增加了100萬股。股東還選出三名二類董事來擔任爲期三年的任期，批准2023年的高級管理人員報酬，並覈准Ernst & Young LLP爲截至2024年12月31日的財年獨立註冊公共會計師事務所。這些提案的細節已經在2024年4月29日向SEC提交的代理聲明中詳述，並在2024年6月5日進行了修訂。修訂計劃的全文已被納入提交的8-K表格的展示部分。
2024年6月13日，Novavax公司舉行年度股東大會，股東們對幾項關鍵提案進行了投票表決。股東批准修訂並重申2015年經修訂的股票激勵計劃，將增加可發行股票數量650萬股。此外，2013年職工購股計劃也經修訂並重申，可發行股票數量增加了100萬股。股東還選出三名二類董事來擔任爲期三年的任期，批准2023年的高級管理人員報酬，並覈准Ernst & Young LLP爲截至2024年12月31日的財年獨立註冊公共會計師事務所。這些提案的細節已經在2024年4月29日向SEC提交的代理聲明中詳述，並在2024年6月5日進行了修訂。修訂計劃的全文已被納入提交的8-K表格的展示部分。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息